Comparing advanced and classical immunotherapy for lymphoma treatment
Official title: Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed/Refractory Lymphoma Patients
Run by Seoul St. Mary's Hospital · NCT06796517 · Data updated 2026-11-12
This study is testing whether newer immunotherapy treatments for high-grade B cell lymphoma work better and are safer than traditional methods for adults who have already had treatment that didn't work.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years to 74 Years |
| Sex | All |
| Enrollment | 72 (estimated) |
| Sponsor | Seoul St. Mary's Hospital Academic / other |
| Drugs / interventions | CAR-T |
| Locations | 2 sites (Seoul and 1 other locations) |
| Status | Recruiting |
| Started | June 26, 2024 |
| Main results expected | December 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | January 28, 2025 |
| Trial ID | NCT06796517 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 19 to 74 years diagnosed with specific types of high-grade B cell lymphoma after January 2015 who have received prior immunochemotherapy.
✕Probably not a fit
Patients who have progressed to acute leukemia, developed solid tumors during treatment, or have active infections may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the effectiveness of advanced immunochemotherapy, including CAR-T therapy, bispecific antibodies, and antibody-drug conjugates, against classical immunochemotherapy methods such as proteasome inhibitors and monoclonal antibodies in patients with relapsed or refractory high-grade B cell lymphoma. Researchers will analyze survival outcomes and treatment-related safety profiles by comparing patient data from electronic medical records and laboratory findings. The study focuses on adults diagnosed with specific types of lymphoma since January 2015 who have previously undergone immunochemotherapy.
Why it matters
Potential benefit: If successful, this study could lead to improved survival outcomes for patients with relapsed or refractory high-grade B cell lymphoma.
How similar studies have gone: Other studies have shown promising results with advanced immunotherapy approaches, suggesting potential for success in this area.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 19 to 74 years. * Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma * Patients who have received immunochemotherapy as treatment for relapsed/refractory lymphoma Exclusion Criteria: * Patients who have progressed to acute leukemia * Patients who developed solid tumor during treatment * Patients with active infectious status (acute pneumonia, viral infection, active hepatitis B state, or active pulmonary tuberculosis etc.)
Where it's running
-
Seoul St. Mary Hospital
Seoul, South Korea Recruiting -
Yeoido St. Mary Hospital
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Sung-Soo Park, MD. PhD.
- Email: sspark@catholic.ac.kr
- Phone: +82-02-2258-6754
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating SGR-1505 for treating mature B-cell neoplasms
This study is testing a new oral medication called SGR-1505 to see if it is safe and effective for people with certain types of B-cell lymphomas that have not responded to other treatments.
-
Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL
This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.
-
Epcoritamab plus dose‑adjusted EPOCH‑R for aggressive B‑cell lymphoma
This trial tests whether adding epcoritamab to dose‑adjusted EPOCH‑R chemotherapy can safely improve outcomes for adults with untreated aggressive B‑cell non‑Hodgkin lymphoma.
-
Preventing CAR-T cell toxicities with emapalumab
This study is testing if a drug called emapalumab can help prevent side effects in people with large B-cell non-Hodgkin's lymphoma who are receiving another treatment called axicabtagene ciloleucel.
-
Gene therapy for certain blood cancers
This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.
-
Using modified T cells to treat relapsed or refractory Non-Hodgkin Lymphoma
This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.